Storia in 2 fonti

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.

AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and royalties.